Hydroxychloroquine and Azithromycin to Treat Patients With COVID-19: Both Friends and Foes?
作者信息
Mégarbane Bruno, Scherrmann Jean-Michel
机构信息
Department of Medical and Toxicological Critical Care, Lariboisière Hospital, Federation of Toxicology APHP, University of Paris, INSERM UMRS-1144, Paris, France.
Faculty of Pharmacy, University of Paris, INSERM UMRS-1144, Paris, France.
出版信息
J Clin Pharmacol. 2020 Jul;60(7):808-814. doi: 10.1002/jcph.1646. Epub 2020 May 20.
Abstract
摘要
相似文献
1
Hydroxychloroquine and Azithromycin to Treat Patients With COVID-19: Both Friends and Foes?羟氯喹和阿奇霉素用于治疗新冠肺炎患者：是益友还是劲敌？
J Clin Pharmacol. 2020 Jul;60(7):808-814. doi: 10.1002/jcph.1646. Epub 2020 May 20.
2
Hydroxychloroquine as prophylaxis or treatment for COVID-19: What does the evidence say?羟氯喹作为 COVID-19 的预防或治疗药物：证据说了什么？
Indian J Public Health. 2020 Jun;64(Supplement):S125-S127. doi: 10.4103/ijph.IJPH_496_20.
3
QT Interval Control to Prevent Torsades de Pointes during Use of Hydroxychloroquine and/or Azithromycin in Patients with COVID-19.在新冠肺炎患者使用羟氯喹和/或阿奇霉素期间控制QT间期以预防尖端扭转型室速
Arq Bras Cardiol. 2020 Jun;114(6):1061-1066. doi: 10.36660/abc.20200389. Epub 2020 Jul 3.
4
Assessment of QT Intervals in a Case Series of Patients With Coronavirus Disease 2019 (COVID-19) Infection Treated With Hydroxychloroquine Alone or in Combination With Azithromycin in an Intensive Care Unit.评估单独使用羟氯喹或联合使用阿奇霉素在重症监护病房治疗的 2019 年冠状病毒病（COVID-19）感染患者的 QT 间期。
JAMA Cardiol. 2020 Sep 1;5(9):1067-1069. doi: 10.1001/jamacardio.2020.1787.
5
Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19).COVID-19 住院患者使用羟氯喹（无论是否联合使用阿奇霉素）导致 QT 间期延长的风险。
JAMA Cardiol. 2020 Sep 1;5(9):1036-1041. doi: 10.1001/jamacardio.2020.1834.
6
Hydroxychloroquine and azithromycin as potential treatments for COVID-19; clinical status impacts the outcome.羟氯喹啉和阿奇霉素作为新型冠状病毒肺炎的潜在治疗药物；临床状况影响治疗结果。
J Pharmacokinet Pharmacodyn. 2020 Jun;47(3):187-188. doi: 10.1007/s10928-020-09689-x. Epub 2020 May 13.
7
Effect of Chloroquine, Hydroxychloroquine, and Azithromycin on the Corrected QT Interval in Patients With SARS-CoV-2 Infection.氯喹、羟氯喹和阿奇霉素对 SARS-CoV-2 感染患者校正 QT 间期的影响。
Circ Arrhythm Electrophysiol. 2020 Jun;13(6):e008662. doi: 10.1161/CIRCEP.120.008662. Epub 2020 Apr 29.
8
Acute meningoencephalitis in a patient with COVID-19.一名新冠肺炎患者出现急性脑膜脑炎。
Rev Neurol (Paris). 2020 Jun;176(6):519-521. doi: 10.1016/j.neurol.2020.04.014. Epub 2020 May 11.
9
Experience With Hydroxychloroquine and Azithromycin in the Coronavirus Disease 2019 Pandemic: Implications for QT Interval Monitoring.羟氯喹和阿奇霉素在 2019 冠状病毒病大流行中的应用经验：对 QT 间期监测的影响。
J Am Heart Assoc. 2020 Jun 16;9(12):e017144. doi: 10.1161/JAHA.120.017144. Epub 2020 May 28.
10
Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection.氯喹、羟氯喹和阿奇霉素用于治疗新型冠状病毒肺炎（SARS-CoV-2感染）时的安全性考量
CMAJ. 2020 Apr 27;192(17):E450-E453. doi: 10.1503/cmaj.200528. Epub 2020 Apr 8.
引用本文的文献
1
Efficacy of Ivermectin, Chloroquine/Hydroxychloroquine, and Azithromycin in Managing COVID-19: A Systematic Review of Phase III Clinical Trials.伊维菌素、氯喹/羟氯喹及阿奇霉素治疗新冠肺炎的疗效：III期临床试验的系统评价
Biomedicines. 2024 Sep 27;12(10):2206. doi: 10.3390/biomedicines12102206.
2
Antihistamines as an early treatment for Covid-19.抗组胺药作为新冠肺炎的早期治疗方法。
Heliyon. 2023 May;9(5):e15772. doi: 10.1016/j.heliyon.2023.e15772. Epub 2023 Apr 25.
3
Identification of a novel immune-inflammatory signature of COVID-19 infections, and evaluation of pharmacokinetics and therapeutic potential of RXn-02, a novel small-molecule derivative of quinolone.鉴定 COVID-19 感染的新型免疫炎症特征，并评估新型喹诺酮类小分子衍生物 RXn-02 的药代动力学和治疗潜力。
Comput Biol Med. 2022 Sep;148:105814. doi: 10.1016/j.compbiomed.2022.105814. Epub 2022 Jul 11.
4
Cancer vs. SARS-CoV-2 induced inflammation, overlapping functions, and pharmacological targeting.癌症与SARS-CoV-2引发的炎症、重叠功能及药物靶向治疗
Inflammopharmacology. 2021 Apr;29(2):343-366. doi: 10.1007/s10787-021-00796-w. Epub 2021 Mar 15.
5
Therapeutic Strategies in the Management of COVID-19.新型冠状病毒肺炎治疗策略
Front Mol Biosci. 2021 Feb 4;7:636738. doi: 10.3389/fmolb.2020.636738. eCollection 2020.
6
Antihistamines and azithromycin as a treatment for COVID-19 on primary health care - A retrospective observational study in elderly patients.抗组胺药和阿奇霉素治疗初级保健中的 COVID-19-老年患者的回顾性观察研究。
Pulm Pharmacol Ther. 2021 Apr;67:101989. doi: 10.1016/j.pupt.2021.101989. Epub 2021 Jan 16.
7
Utilitarian Principlism as a Framework for Crisis Healthcare Ethics.效用主义原则作为危机医疗保健伦理学的框架。
HEC Forum. 2021 Jun;33(1-2):45-60. doi: 10.1007/s10730-020-09431-7. Epub 2021 Jan 15.
8
COVID-19, hydroxychloroquine and sudden cardiac death: implications for clinical practice in patients with rheumatic diseases.COVID-19、羟氯喹和心脏性猝死：对风湿性疾病患者临床实践的影响。
Rheumatol Int. 2021 Feb;41(2):257-273. doi: 10.1007/s00296-020-04759-2. Epub 2021 Jan 1.
9
SARS-CoV-2: From Structure to Pathology, Host Immune Response and Therapeutic Management.严重急性呼吸综合征冠状病毒2：从结构到病理学、宿主免疫反应及治疗管理
Microorganisms. 2020 Sep 24;8(10):1468. doi: 10.3390/microorganisms8101468.
10
Treatments in Covid-19 patients with pre-existing metabolic dysfunction-associated fatty liver disease: A potential threat for drug-induced liver injury?患有代谢相关脂肪性肝病的新冠病毒感染患者的治疗：药物性肝损伤的潜在威胁？
Biochimie. 2020 Dec;179:266-274. doi: 10.1016/j.biochi.2020.08.018. Epub 2020 Sep 3.
本文引用的文献
1
Outcomes of Hydroxychloroquine Usage in United States Veterans Hospitalized with COVID-19.羟氯喹在美国 COVID-19 住院患者中的使用效果。
Med. 2020 Dec 18;1(1):114-127.e3. doi: 10.1016/j.medj.2020.06.001. Epub 2020 Jun 5.
2
Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France.羟氯喹和阿奇霉素联合治疗 COVID-19 患者：法国马赛 1061 例回顾性分析。
Travel Med Infect Dis. 2020 May-Jun;35:101738. doi: 10.1016/j.tmaid.2020.101738. Epub 2020 May 5.
3
In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect.体外试验表明，羟氯喹与阿奇霉素联合使用对 SARS-CoV-2 具有协同作用。
Microb Pathog. 2020 Aug;145:104228. doi: 10.1016/j.micpath.2020.104228. Epub 2020 Apr 25.
4
Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial.高剂量与低剂量磷酸氯喹作为辅助治疗对住院的严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）感染患者的影响：一项随机临床试验。
JAMA Netw Open. 2020 Apr 24;3(4):e208857. doi: 10.1001/jamanetworkopen.2020.8857.
5
Clinical Pharmacology Perspectives on the Antiviral Activity of Azithromycin and Use in COVID-19.临床药理学视角下阿奇霉素的抗病毒活性及其在 COVID-19 中的应用。
Clin Pharmacol Ther. 2020 Aug;108(2):201-211. doi: 10.1002/cpt.1857. Epub 2020 May 12.
6
Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study.羟氯喹和阿奇霉素联合治疗至少随访 6 天的 80 例 COVID-19 患者的临床和微生物学效果：一项前瞻性观察研究。
Travel Med Infect Dis. 2020 Mar-Apr;34:101663. doi: 10.1016/j.tmaid.2020.101663. Epub 2020 Apr 11.
7
Optimizing Hydroxychloroquine Dosing for Patients With COVID-19: An Integrative Modeling Approach for Effective Drug Repurposing.优化 COVID-19 患者的羟氯喹剂量：一种有效的药物再利用的综合建模方法。
Clin Pharmacol Ther. 2020 Aug;108(2):253-263. doi: 10.1002/cpt.1856. Epub 2020 May 12.
8
No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection.对于重症新冠病毒感染患者，没有证据表明羟氯喹和阿奇霉素联合使用能实现快速的抗病毒清除或带来临床益处。
Med Mal Infect. 2020 Jun;50(4):384. doi: 10.1016/j.medmal.2020.03.006. Epub 2020 Mar 30.
9
Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19.新冠病毒病患者中的肾素-血管紧张素-醛固酮系统抑制剂
N Engl J Med. 2020 Apr 23;382(17):1653-1659. doi: 10.1056/NEJMsr2005760. Epub 2020 Mar 30.
10
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).羟氯喹治疗严重急性呼吸综合征冠状病毒 2 （SARS-CoV-2）的体外抗病毒活性和优化剂量设计预测。
Clin Infect Dis. 2020 Jul 28;71(15):732-739. doi: 10.1093/cid/ciaa237.
Zotero 插件